Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H15N2O2.Cl |
| Molecular Weight | 182.649 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)CCOC(N)=O
InChI
InChIKey=AIXAANGOTKPUOY-UHFFFAOYSA-N
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
| Molecular Formula | C6H15N2O2 |
| Molecular Weight | 147.1955 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL220 |
6.0 mM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | MIOSTAT Approved UseIntraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery. Launch Date1972 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Avoidance learning: long-lasting deficits after temporal lobe seizure. | 1969 Dec 12 |
|
| Sustained atrial fibrillation induced by carbachol, methacholine and bethanechol. | 1971 Apr |
|
| [Effects of atropine and scopolamine on the aggressive behavior and convulsions induced by carbachol and eserine injected into the cerebral ventricles of the cat]. | 1980 |
|
| Seizures induced by carbachol, morphine, and leucine-enkephalin: a comparison. | 1983 Apr |
|
| Neuropharmacology of the parasitic trematode, Schistosoma mansoni. | 1983 Jan |
|
| Drug-induced modulation of locomotor hyperactivity induced by picrotoxin in nucleus accumbens. | 1984 Oct |
|
| Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". | 1984 Sep 3 |
|
| A crucial epileptogenic site in the deep prepiriform cortex. | 1985 Oct 17-23 |
|
| Cardiovascular effects of cholinergic agents in the ventral-lateral midbrain periaqueductal gray of the rat. | 1987 Dec |
|
| The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior. | 1988 Feb 16 |
|
| Catalepsy induced by carbachol microinjected into the pontine reticular formation of rats. | 1990 Jul 31 |
|
| Studies on the development of tolerance and potential spinal neurotoxicity after chronic intrathecal carbachol-antinociception in the rat. | 1991 Feb |
|
| Vagus nerve modulates secretin binding sites in the rat forestomach. | 1999 Apr |
|
| Cardiovascular studies on different classes of soft drugs. | 2000 Mar |
|
| Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
| The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines. | 2002 Aug |
|
| Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart. | 2002 May |
|
| Regeneration of cardiomyocytes from bone marrow: Use of mesenchymal stem cell for cardiovascular tissue engineering. | 2003 Mar |
|
| Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. | 2003 Nov |
|
| [Effects of carbachol on apoptosis of peripheral white blood cells and expression of cytokines in rats suffering from gut ischemia/reperfusion injury]. | 2005 Feb |
|
| Actin and non-muscle myosin II facilitate apical exocytosis of tear proteins in rabbit lacrimal acinar epithelial cells. | 2005 Oct 15 |
|
| Theoretical and experimental investigation of calcium-contraction coupling in airway smooth muscle. | 2006 |
|
| Case report: acute unintentional carbachol intoxication. | 2006 |
|
| Novelty exploration elicits a reversal of acute stress-induced modulation of hippocampal synaptic plasticity in the rat. | 2006 Dec 1 |
|
| Muscarinic cholinoceptor activation modulates DNA synthesis and CD40 expression in fibroblast cells. | 2006 Jul |
|
| Gene transfer of neuronal nitric oxide synthase into intracardiac Ganglia reverses vagal impairment in hypertensive rats. | 2007 Feb |
|
| Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells. | 2008 Jul |
|
| Molecular basis of inhibition of substrate hydrolysis by a ligand bound to the peripheral site of acetylcholinesterase. | 2010 Sep 6 |
|
| Antispasmodic effects of eugenol on rat airway smooth muscle. | 2011 Dec |
|
| TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. | 2011 Feb 18 |
|
| Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). | 2011 Sep 25 |
|
| Characterisation of acetylcholinesterase release from neuronal cells. | 2013 Mar 25 |
Patents
Sample Use Guides
MIOSTAT (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Route of Administration:
Other
In the dose-course studies, carbachol showed significant increase in phosphorylation of MYPT1 at Thr696 (p-MYPT1) from concentrations of 15-100 μM based on Western blot results (p < 0.05, ANOVA test). In the time-course studies, treatment of cells with 15 μM of carbachol significantly enhanced the expression of p-MYPT1 from 3 to 15 h (p < 0.05, ANOVA test) and induced the expression of Rho A from 10 to 120 min (p < 0.05, ANOVA test).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:11:00 GMT 2023
by
admin
on
Fri Dec 15 15:11:00 GMT 2023
|
| Record UNII |
8Y164V895Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-ATC |
S01EB02
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-ATC |
N07AB01
Created by
admin on Fri Dec 15 15:11:00 GMT 2023 , Edited by admin on Fri Dec 15 15:11:00 GMT 2023
|
||
|
NDF-RT |
N0000175884
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-VATC |
QS01EB02
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-VATC |
QA03AB92
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5831
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
C47430
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
DB00411
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
32865
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
488
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
SUB06087MIG
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
298
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
m3051
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
D002217
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL965
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
DTXSID9022730
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
3385
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
51-83-2
Created by
admin on Fri Dec 15 15:11:00 GMT 2023 , Edited by admin on Fri Dec 15 15:11:00 GMT 2023
|
PRIMARY | |||
|
6373
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
1092009
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
1999
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
383
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
Carbachol
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
100000081628
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
200-127-3
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
Carbachol
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Duration of Action | PHARMACOKINETIC |
|
INTRAOCULAR ADMINISTRATION PHARMACOKINETIC |
|
||